Cortechs Laboratory

Author Of 1 Presentation

Clinical Outcome Measures Poster Presentation

P0122 - Ocrelizumab in patients with multiple sclerosis: A single center experience.  (ID 668)

Speakers
Presentation Number
P0122
Presentation Topic
Clinical Outcome Measures

Abstract

Background

Multiple Sclerosis is a progressive demyelinating autoimmune disorder that can lead to significant morbidity and mortality. It can be either relapsing remitting i.e Relapsing Remitting Multiple Sclerosis (RRMS) or progressive in nature like Primary Progressive Multiple Sclerosis (PPMS). Several Disease Modifying Treatments (DMT) are used to treat this disorder. Ocrelizumab is a humanized CD20 monoclonal antibody which was approved for management of RRMS and PPMS in 2017. Trials such OPERA I and II as well as ORATORIO has shown improved clinical outcomes in patients with RRMS and PPMS respectively.

Objectives

We aim to study the clinical disease progression including disability scores and imaging findings such as volumetric analysis of several central structures in patients being treated with Ocrelizumab at baseline and 12 months.

Methods

We enrolled a total of 124 patients that were seen at our institute, who are currently being treated with Ocrelizumab (92 with RRMS and 32 with PPMS) between August 2017 to July 2020. Clinical data was obtained from their medical records including Expanded Disability Status Scale (EDSS) and Timed 25 Foot Walk (T25FW) at baseline and 12 months. MRI of the brain, which included T1-w, T2-w, T2-FLAIR, post gadolinium T1-MRAGE sequences were also collected. LesionQuant software, developed by CorTechs laboratory will be used to obtain volumes of the cortical gray matter, white matter, hippocampi and white matter lesion load in the periventricular, juxtacortical, infratentorial and deep cerebral white matter areas.

Results

When independent paired t- test was performed there was significant improvement in the T25FW over time (t= 3.19, n=47; p=0.003 Cohen’s d= 0.46) but no such changes were observed with the EDSS scores (t= 1.58, n= 120; p=0.118 Cohen’s d= 0.14). Means of T25FW before and after intervention were 10.98 seconds and 9.49 seconds respectively. Means of EDSS scores before and after interventions were 3.58 and 3.52 respectively. We’re currently in the process of obtaining volumetric measure of the structures mentioned above and correlating them with the clinical scales in the near future.

Conclusions

In 31 participants with PPMS, EDSS score improved in 6 (19%), was stable in 22 (71%), and deteriorated in 3 (10%). In 89 participants with RRMS, EDSS score improved in 3 (3%), was stable in 76 (86%), and deteriorated in 10 (11%). We hope to further explore the effect of medication by computing imaging features in the near future.

Collapse